Atrial Fibrillation Ablation Should Be First-line Therapy in Patients with Heart Failure Reduced Ejection Fraction

Pradyumna Agasthi1, Andrew Tseng2, Justin Z Lee1

  • 1Department of Cardiovascular Diseases, Mayo Clinic, 5777 East Mayo Boulevard, Phoenix, AZ 85054, USA.

Cardiology Clinics
|March 31, 2019
PubMed

Insights

Catheter ablation improves outcomes for atrial fibrillation patients with reduced ejection fraction heart failure. Evidence is less strong for those with preserved ejection fraction heart failure.

Area of Science:

  • Cardiology
  • Electrophysiology
  • Heart Failure Management

Background:

  • Atrial fibrillation (AF) is a common arrhythmia.
  • Heart failure (HF) affects millions worldwide.
  • The interplay between AF and HF, particularly with varying ejection fractions, requires further investigation.

Purpose of the Study:

  • To evaluate the efficacy of catheter ablation for AF in patients with HF with reduced ejection fraction (HFrEF).
  • To compare catheter ablation outcomes against standard medical therapy in HFrEF patients.
  • To assess the current evidence for catheter ablation in HF with preserved ejection fraction (HFpEF) patients.

Main Methods:

  • Systematic review and meta-analysis of existing studies.
  • Comparison of patient-centered outcomes (mortality, readmission, AF recurrence).
  • Analysis stratified by ejection fraction status (HFrEF vs. HFpEF).

Main Results:

  • Catheter ablation significantly improved mortality, HF readmission, and AF recurrence in HFrEF patients compared to standard therapy.
  • Standard therapy included medical management and/or device implantation.
  • Evidence supporting catheter ablation in HFpEF patients was found to be less robust.

Conclusions:

  • Catheter ablation is a beneficial treatment for AF in patients with HFrEF.
  • Further research is needed to establish the role of catheter ablation in HFpEF.
  • Optimizing AF management in HF patients is crucial for improving prognoses.

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
301
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.2K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
776
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
837
Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
11.7K
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
893